The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

CD19 CAR-T for Relapsed ALL and Non-Hodgkin Lymphoma

Chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell malignancies

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is CD19 CAR-T for Relapsed ALL and Non-Hodgkin Lymphoma?

CAR-T cells are autologous T cells genetically engineered to express chimeric receptors targeting CD19 surface antigen on B cells.

Manufacturing involves apheresis collection of patient T cells, viral vector transduction inserting CAR construct and ex vivo expansion.

Lymphodepleting chemotherapy with fludarabine-cyclophosphamide creates favorable environment for CAR-T expansion and activity.

FDA-approved products differ in manufacturing platforms, costimulatory domains and clinical indications.

Persistent B-cell aplasia from on-target effect requires immunoglobulin replacement therapy for hypogammaglobulinemia.

Symptoms

Relapsed/refractory ALL or B-NHL after multiple lines of conventional therapy define eligibility for CAR-T.
Pre-CAR-T evaluation includes disease assessment, organ function, infection screening and apheresis adequacy.
Cytokine release syndrome typically manifests fever, hypotension, hypoxia within first weeks after infusion.
ICANS presents with confusion, aphasia, seizures, decreased consciousness requiring neurologic monitoring.
B-cell aplasia produces persistent hypogammaglobulinemia and infection susceptibility.

Risk Factors

High disease burden at infusion time increases CRS severity and may necessitate bridging therapy.
Performance status decline and organ dysfunction limit CAR-T eligibility requiring careful patient selection.
Active infections require resolution before CAR-T due to immunosuppression and lymphodepletion.
Prior CD19-targeted therapy may produce antigen escape variants reducing CAR-T efficacy.
Age, comorbidities and access to specialized centers affect treatment feasibility and outcomes.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Relapsed/refractory CD19-positive B-cell malignancy after multiple lines of therapy warrants CAR-T evaluation.
  • Specialized CAR-T center referral required for treatment delivery and management capabilities.
  • Post-infusion fever, hypotension, neurological symptoms require immediate evaluation and management.
  • Infection symptoms during prolonged B-cell aplasia warrant prompt antimicrobial therapy.
  • Long-term follow-up monitors disease response, B-cell recovery, secondary malignancy risk and gene therapy registry participation.

Treatment Methods

01
Bridging therapy between leukapheresis and CAR-T infusion to control disease and maintain eligibility.
02
Standard lymphodepleting chemotherapy with fludarabine 30 mg/m2 and cyclophosphamide 500 mg/m2 daily for 3 days.
03
Tocilizumab IL-6 receptor antibody for grade 2 or higher CRS with corticosteroids for severe cases.
04
Corticosteroid management of ICANS with anakinra emerging for refractory cases and preventive strategies investigation.
05
Comprehensive supportive care including infection prophylaxis with PJP and HSV/VZV antivirals, IVIG for hypogammaglobulinemia, hematopoietic recovery support, monitoring for relapse including measurable residual disease assessment and long-term toxicity surveillance optimizes outcomes from this transformative cellular therapy.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.